Shares of Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) fell 3.8% during trading on Wednesday . The company traded as low as $41.76 and last traded at $41.76, with a volume of 322,528 shares traded. The stock had previously closed at $43.40.

A number of research firms have commented on PCRX. Mizuho reaffirmed an “outperform” rating and set a $64.00 target price on shares of Pacira Pharmaceuticals in a report on Friday, July 1st. Wedbush reissued an “outperform” rating and issued a $113.00 price target on shares of Pacira Pharmaceuticals in a report on Wednesday, May 4th. Zacks Investment Research lowered shares of Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, July 29th. Piper Jaffray Cos. reissued an “overweight” rating and issued a $81.00 price target on shares of Pacira Pharmaceuticals in a report on Wednesday, August 3rd. Finally, TheStreet lowered shares of Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, May 2nd. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Pacira Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $73.64.

The firm’s market cap is $1.48 billion. The company has a 50 day moving average of $39.78 and a 200 day moving average of $47.66.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings data on Thursday, August 4th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.16. During the same quarter in the prior year, the business earned $0.20 earnings per share. The business had revenue of $69.60 million for the quarter, compared to analyst estimates of $67.80 million. The firm’s quarterly revenue was up 17.8% compared to the same quarter last year. Equities analysts anticipate that Pacira Pharmaceuticals Inc. will post $0.42 earnings per share for the current fiscal year.

In related news, Director Mark A. Kronenfeld sold 900 shares of the firm’s stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $46.95, for a total transaction of $42,255.00. Following the transaction, the director now directly owns 2,950 shares of the company’s stock, valued at $138,502.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Kristen Marie Williams sold 600 shares of the firm’s stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $47.20, for a total transaction of $28,320.00. Following the transaction, the chief accounting officer now directly owns 6,900 shares in the company, valued at $325,680. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Pacira Pharmaceuticals stock. KBC Group NV boosted its position in shares of Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) by 2,685.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,024 shares of the company’s stock after buying an additional 27,018 shares during the period. KBC Group NV owned 0.08% of Pacira Pharmaceuticals worth $2,152,000 as of its most recent SEC filing.

Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.